Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Restifo Website

Nicholas P. Restifo, M.D.

Selected Publications

1)  Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, Hughes MS, Laurencot CM, Rosenberg SA.
Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma.
J. Clin. Oncol. 2013.
2)  Chinnasamy D, Tran E, Yu Z, Morgan RA, Restifo NP, Rosenberg SA.
Simultaneous Targeting of Tumor Antigens and the Tumor Vasculature Using T Lymphocyte Transfer Synergize to Induce Regression of Established Tumors in Mice.
Cancer Res. 2013.
3)  Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA.
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
J. Immunother. 36: 133-51, 2013.
4)  Kerkar SP, Leonardi AJ, van Panhuys N, Zhang L, Yu Z, Crompton JG, Pan JH, Palmer DC, Morgan RA, Rosenberg SA, Restifo NP.
Collapse of the Tumor Stroma is Triggered by IL-12 Induction of Fas.
Mol. Ther. [Epub ahead of print], 2013.
5)  Hanada K, Restifo NP.
Double or nothing on cancer immunotherapy.
Nat. Biotechnol. 31: 33-4, 2013.
6)  Muranski P, Restifo NP.
Essentials of Th17 cell commitment and plasticity.
Blood. 121: 2402-14, 2013.
7)  Lugli E, Gattinoni L, Roberto A, Mavilio D, Price DA, Restifo NP, Roederer M.
Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells.
Nat Protoc. 8: 33-42, 2013.
8)  Crompton JG, Rao M, Restifo NP.
Memoirs of a reincarnated T cell.
Cell Stem Cell. 12: 6-8, 2013.
9)  Dudda JC, Salaun B, Ji Y, Palmer DC, Monnot GC, Merck E, Boudousquie C, Utzschneider DT, Escobar TM, Perret R, Muljo SA, Hebeisen M, Rufer N, Zehn D, Donda A, Restifo NP, Held W, Gattinoni L, Romero P.
MicroRNA-155 Is Required for Effector CD8(+) T Cell Responses to Virus Infection and Cancer.
Immunity. 38: 742-53, 2013.
10)  Yang S, Ji Y, Gattinoni L, Zhang L, Yu Z, Restifo NP, Rosenberg SA, Morgan RA.
Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails.
Cancer Immunol. Immunother. 62: 727-36, 2013.
11)  Gattinoni L, Restifo NP.
Moving T memory stem cells to the clinic.
Blood. 121: 567-8, 2013.
12)  Lugli E, Dominguez MH, Gattinoni L, Chattopadhyay PK, Bolton DL, Song K, Klatt NR, Brenchley JM, Vaccari M, Gostick E, Price DA, Waldmann TA, Restifo NP, Franchini G, Roederer M.
Superior T memory stem cell persistence supports long-lived T cell memory.
J. Clin. Invest. 123: 594-9, 2013.
13)  Zhong S, Malecek K, Johnson LA, Yu Z, Vega-Saenz de Miera E, Darvishian F, McGary K, Huang K, Boyer J, Corse E, Shao Y, Rosenberg SA, Restifo NP, Osman I, Krogsgaard M.
T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy.
Proc. Natl. Acad. Sci. U.S.A. 110: 6973-8, 2013.
14)  Restifo NP, Dudley ME, Rosenberg SA.
Adoptive immunotherapy for cancer: harnessing the T cell response.
Nat. Rev. Immunol. 12: 269-81, 2012.
15)  Kerkar SP, Restifo NP.
Cellular constituents of immune escape within the tumor microenvironment.
Cancer Res. 72: 3125-30, 2012.
16)  Jensen SM, Twitty CG, Maston LD, Antony PA, Lim M, Hu HM, Petrausch U, Restifo NP, Fox BA.
Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence.
J. Immunol. 189: 767-76, 2012.
17)  Zhang L, Yu Z, Muranski P, Palmer DC, Restifo NP, Rosenberg SA, Morgan RA.
Inhibition of TGF-ß signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.
Gene Ther. [Epub ahead of print], 2012.
18)  Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP, Rosenberg SA.
Local Delivery of lnterleukin-12 using T cells Targeting Vascular Endothelial Growth Factor Receptor-2 Eradicates Multiple Vascularized Tumors in Mice.
Clin Cancer Res. 18: 1672-83, 2012.
19)  Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, Flynn P, Gattinoni L, Heath JR, Kalos M, Marincola FM, Miller JS, Mostoslavsky G, Powell DJ, Rao M, Restifo NP, Rosenberg SA, O'Shea J, Melief CJ.
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer.
J Transl Med. 10: 48, 2012.
20)  Zou W, Restifo NP.
Nine lives for TH9s?.
Nat. Med. 18: 1177-8, 2012.
21)  Gattinoni L, Klebanoff CA, Restifo NP.
Paths to stemness: building the ultimate antitumour T cell.
Nat. Rev. Cancer. 12: 671-84, 2012.
22)  Klebanoff CA, Gattinoni L, Restifo NP.
Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?.
J. Immunother. 35: 651-60, 2012.
23)  Kerkar SP, Restifo NP.
The power and pitfalls of IL-12.
Blood. 119: 4096-7, 2012.
24)  Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, Aghamolla T, Alvarez-Downing MM, Lee CC, Singh S, Li T, Dudley ME, Restifo NP, Rosenberg SA, Kammula US.
The stoichiometric production of IL-2 and IFN-? mRNA defines memory T cells that can self-renew after adoptive transfer in humans.
Sci Transl Med. 4: 149ra120, 2012.
25)  Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, Wang E, Douek DC, Price DA, June CH, Marincola FM, Roederer M, Restifo NP.
A human memory T cell subset with stem cell-like properties.
Nat. Med. 17: 1290-7, 2011.
26)  Chinnasamy N, Wargo JA, Yu Z, Rao M, Frankel TL, Riley JP, Hong JJ, Parkhurst MR, Feldman SA, Schrump DS, Restifo NP, Robbins PF, Rosenberg SA, Morgan RA.
A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
J. Immunol. 186: 685-96, 2011.
27)  Amos SM, Pegram HJ, Westwood JA, John LB, Devaud C, Clarke CJ, Restifo NP, Smyth MJ, Darcy PK, Kershaw MH.
Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice.
Cancer Immunol. Immunother. 60: 671-83, 2011.
28)  Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, Borman ZA, Kerkar SP, Scott CD, Finkelstein S, Rosenberg SA, Restifo NP.
Determinants of successful CD8+ T cell adoptive immunotherapy for large established tumors in mice.
Clin Cancer Res. 17: 5343-52, 2011.
29)  Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME.
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy.
Clin Cancer Res. 17: 4550-7, 2011.
30)  Yang S, Gattinoni L, Liu F, Ji Y, Yu Z, Restifo NP, Rosenberg SA, Morgan RA.
Erratum to: In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells.
Cancer Immunol. Immunother. 60: 751, 2011.
31)  Kerkar SP, Sanchez-Perez L, Yang S, Borman ZA, Muranski P, Ji Y, Chinnasamy D, Kaiser AD, Hinrichs CS, Klebanoff CA, Scott CD, Gattinoni L, Morgan RA, Rosenberg SA, Restifo NP.
Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies.
J. Immunother. 34: 343-52, 2011.
32)  Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, Klebanoff CA, Johnson LA, Kerkar SP, Yang S, Muranski P, Palmer DC, Scott CD, Morgan RA, Robbins PF, Rosenberg SA, Restifo NP.
Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.
Blood. 117: 808-14, 2011.
33)  Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, Leonardi AJ, Morgan RA, Wang E, Marincola FM, Trinchieri G, Rosenberg SA, Restifo NP.
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.
J. Clin. Invest. 121: 4746-57, 2011.
34)  Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, Rosenberg SA, Morgan RA.
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.
Mol. Ther. 19: 751-9, 2011.
35)  Yang S, Luca G, Liu F, Ji Y, Yu Z, Restifo NP, Rosenberg SA, Morgan RA.
In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells.
Cancer Immunol. Immunother. 60: 739-49, 2011.
36)  Ascierto ML, Worschech A, Yu Z, Adams S, Reinboth J, Chen NG, Pos Z, Roychoudhuri R, Di Pasquale G, Bedognetti D, Uccellini L, Rossano F, Ascierto PA, Stroncek DF, Restifo NP, Wang E, Szalay AA, Marincola FM.
Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68.
BMC Cancer. 11: 451, 2011.
37)  Liu Y, Tian X, Leitner WW, Aldridge ME, Zheng J, Yu Z, Restifo NP, Weiss R, Scheiblhofer S, Xie C, Sun R, Cheng G, Zeng G.
Polymeric structure and host Toll-like receptor 4 dictate immunogenicity of NY-ESO-1 antigen in vivo.
J. Biol. Chem. 286: 37077-84, 2011.
38)  Hu G, Schones DE, Cui K, Ybarra R, Northrup D, Tang Q, Gattinoni L, Restifo NP, Huang S, Zhao K.
Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1.
Genome Res. 21: 1650-8, 2011.
39)  Ji Y, Pos Z, Rao M, Klebanoff CA, Yu Z, Sukumar M, Reger RN, Palmer DC, Borman ZA, Muranski P, Wang E, Schrump DS, Marincola FM, Restifo NP, Gattinoni L.
Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells.
Nat. Immunol. 12: 1230-7, 2011.
40)  Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA.
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.
Mol. Ther. 19: 620-6, 2011.
41)  Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ, Roychoudhuri R, Ferreyra GA, Shen W, Durum SK, Feigenbaum L, Palmer DC, Antony PA, Chan CC, Laurence A, Danner RL, Gattinoni L, Restifo NP.
Th17 cells are long lived and retain a stem cell-like molecular signature.
Immunity. 35: 972-85, 2011.
42)  Klebanoff CA, Acquavella N, Yu Z, Restifo NP.
Therapeutic cancer vaccines: are we there yet?.
Immunol. Rev. 239: 27-44, 2011.
43)  Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA.
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
J. Clin. Oncol. 29: 917-24, 2011.
44)  Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA.
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.
Blood. 116: 3875-86, 2010.
45)  Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA.
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.
Cancer Res. 70: 6171-80, 2010.
46)  Frankel TL, Burns WR, Peng PD, Yu Z, Chinnasamy D, Wargo JA, Zheng Z, Restifo NP, Rosenberg SA, Morgan RA.
Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase.
J Immunol. 184: 5988-98, 2010.
47)  Restifo NP.
Can antitumor immunity help to explain.
Cancer Cell. 18: 403-5, 2010.
48)  Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich JR, Prieto PA, Hong JJ, Langan RC, Zlott DA, Morton KE, White DE, Laurencot CM, Rosenberg SA.
CD8+ enriched.
Clin. Cancer Res. 16: 6122-31, 2010.
49)  Flatz L, Hegazy AN, Bergthaler A, Verschoor A, Claus C, Fernandez M, Gattinoni L, Johnson S, Kreppel F, Kochanek S, Broek M, Radbruch A, Lévy F, Lambert PH, Siegrist CA, Restifo NP, Löhning M, Ochsenbein AF, Nabel GJ, Pinschewer DD.
Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity.
Nat. Med. 16: 339-45, 2010.
50)  Rosenberg SA, Yang JC, Kammula US, Hughes MS, Restifo NP, Schwarz SL, Morton KE, Laurencot CM, Sherry RM.
Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine.
J. Immunother. 33: 626-9, 2010.
51)  Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, Feldman SA, Restifo NP, Rosenberg SA.
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.
J. Clin. Invest. 120: 3953-68, 2010.
52)  Rausch MP, Irvine KR, Antony PA, Restifo NP, Cresswell P, Hastings KT.
GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1.
J. Immunol. 185: 2828-35, 2010.
53)  Bolinger B, Engeler D, Krebs P, Miller S, Firner S, Hoffmann M, Palmer DC, Restifo NP, Tian Y, Clavien PA, Ludewig B.
IFN-gamma-receptor signaling ameliorates transplant vasculopathy through attenuation of CD8+ T-cell-mediated injury of vascular endothelial cells.
Eur. J. Immunol. 40: 733-43, 2010.
54)  Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP.
Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.
J. Immunother. 33: 1-7, 2010.
55)  Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, Muranski P, Restifo NP, Antony PA.
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.
J. Exp. Med. 207: 651-67, 2010.
56)  Zou W, Restifo NP.
T(H)17 cells in tumour immunity and immunotherapy.
Nat. Rev. Immunol. 10: 248-56, 2010.
57)  Ha SP, Klemen ND, Kinnebrew GH, Brandmaier AG, Marsh J, Hangoc G, Palmer DC, Restifo NP, Cornetta K, Broxmeyer HE, Touloukian CE.
Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity.
J. Clin. Invest. 120: 4273-88, 2010.
58)  Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, Restifo NP, Allison JP.
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.
J. Exp. Med. 207: 637-50, 2010.
59)  Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, Palmer DC, Reger RN, Borman ZA, Zhang L, Morgan RA, Gattinoni L, Rosenberg SA, Trinchieri G, Restifo NP.
Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.
Cancer Res. 70: 6725-34, 2010.
60)  Gattinoni L, Ji Y, Restifo NP.
Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy.
Clin. Cancer Res. 16: 4695-701, 2010.
61)  Muranski P, Restifo NP.
Adoptive immunotherapy of cancer using CD4(+) T cells.
Curr. Opin. Immunol. 21: 200-8, 2009.
62)  Schumacher TN, Restifo NP.
Adoptive T cell therapy of cancer.
Curr. Opin. Immunol. 21: 187-9, 2009.
63)  Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC, Ji Y, Reger RN, Leonard WJ, Danner RL, Rosenberg SA, Restifo NP.
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.
Proc. Natl. Acad. Sci. U.S.A. 106: 17469-74, 2009.
64)  Muranski P, Restifo NP.
Does IL-17 promote tumor growth?.
Blood. 114: 231-2, 2009.
65)  Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CR, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, Vanwaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA.
Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
Blood. 114: 535-46, 2009.
66)  Brandmaier AG, Leitner WW, Ha SP, Sidney J, Restifo NP, Touloukian CE.
High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction.
J. Immunother. 32: 677-88, 2009.
67)  Yeh S, Karne NK, Kerkar SP, Heller CK, Palmer DC, Johnson LA, Li Z, Bishop RJ, Wong WT, Sherry RM, Yang JC, Dudley ME, Restifo NP, Rosenberg SA, Nussenblatt RB.
Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.
Ophthalmology. 116: 981-989.e1, 2009.
68)  Gattinoni L, Klebanoff CA, Restifo NP.
Pharmacologic induction of CD8+ T cell memory: better living through chemistry.
Sci Transl Med. 1: 11ps12, 2009.
69)  Klebanoff CA, Yu Z, Hwang LN, Palmer DC, Gattinoni L, Restifo NP.
Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.
Blood. 114: 1776-83, 2009.
70)  Palmer DC, Restifo NP.
Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function.
Trends Immunol. 30: 592-602, 2009.
71)  Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C.
T helper 17 cells promote cytotoxic T cell activation in tumor immunity.
Immunity. 31: 787-98, 2009.
72)  Hinrichs CS, Kaiser A, Paulos CM, Cassard L, Sanchez-Perez L, Heemskerk B, Wrzesinski C, Borman ZA, Muranski P, Restifo NP.
Type 17 CD8+ T cells display enhanced anti-tumor immunity.
Blood. 114: 596-9, 2009.
73)  Tewalt EF, Grant JM, Granger EL, Palmer DC, Heuss ND, Gregerson DS, Restifo NP, Norbury CC.
Viral sequestration of antigen subverts cross presentation to CD8(+) T cells.
PLoS Pathog. 5: e1000457, 2009.
74)  Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Garvin LM, Paulos CM, Muranski P, Restifo NP.
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells.
Nat. Med. 15: 808-13, 2009.
75)  Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA.
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
J. Clin. Oncol. 26: 5233-9, 2008.
76)  Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME.
Adoptive cell transfer: a clinical path to effective cancer immunotherapy.
Nat. Rev. Cancer. 8: 299-308, 2008.
77)  Boni A, Muranski P, Cassard L, Wrzesinski C, Paulos CM, Palmer DC, Gattinoni L, Hinrichs CS, Chan CC, Rosenberg SA, Restifo NP.
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.
Blood. 112: 4746-54, 2008.
78)  Rosenberg SA, Dudley ME, Restifo NP.
Cancer immunotherapy.
N. Engl. J. Med. 359: 1072, 2008.
79)  Yang S, Cohen CJ, Peng PD, Zhao Y, Cassard L, Yu Z, Zheng Z, Jones S, Restifo NP, Rosenberg SA, Morgan RA.
Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition.
Gene Ther. 15: 1411-23, 2008.
80)  Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, Powell DJ, Klebanoff CA, Finkelstein SE, Fariss RN, Yu Z, Nussenblatt RB, Rosenberg SA, Restifo NP.
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity.
Proc. Natl. Acad. Sci. U.S.A. 105: 8061-6, 2008.
81)  Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ, Restifo NP.
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.
Blood. 111: 5326-33, 2008.
82)  Bolinger B, Krebs P, Tian Y, Engeler D, Scandella E, Miller S, Palmer DC, Restifo NP, Clavien PA, Ludewig B.
Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigen.
Blood. 111: 4588-95, 2008.
83)  Abad JD, Wrzensinski C, Overwijk W, De Witte MA, Jorritsma A, Hsu C, Gattinoni L, Cohen CJ, Paulos CM, Palmer DC, Haanen JB, Schumacher TN, Rosenberg SA, Restifo NP, Morgan RA.
T-cell receptor gene therapy of established tumors in a murine melanoma model.
J. Immunother. 31: 1-6, 2008.
84)  Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM, Rosenberg SA.
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines.
Clin. Cancer Res. 14: 5610-8, 2008.
85)  Ahn S, Lee G, Yang SJ, Lee D, Lee S, Shin HS, Kim MC, Lee KN, Palmer DC, Theoret MR, Jenkinson EJ, Anderson G, Restifo NP, Kim MG.
TSCOT+ thymic epithelial cell-mediated sensitive CD4 tolerance by direct presentation.
PLoS Biol. 6: e191, 2008.
86)  Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC, Restifo NP.
Tumor-specific Th17-polarized cells eradicate large established melanoma.
Blood. 112: 362-73, 2008.
87)  Zhao Y, Parkhurst MR, Zheng Z, Cohen CJ, Riley JP, Gattinoni L, Restifo NP, Rosenberg SA, Morgan RA.
Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling.
Cancer Res. 67: 2425-9, 2007.
88)  Wrzesinski C, Paulos CM, Gattinoni L, Palmer DC, Kaiser A, Yu Z, Rosenberg SA, Restifo NP.
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells.
J. Clin. Invest. 117: 492-501, 2007.
89)  Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z, Gattinoni L, Antony PA, Rosenberg SA, Restifo NP.
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.
J. Clin. Invest. 117: 2197-204, 2007.
90)  Borbulevych OY, Insaidoo FK, Baxter TK, Powell DJ, Johnson LA, Restifo NP, Baker BM.
Structures of MART-1(26/27-35) Peptide/HLA-A2 Complexes Reveal a Remarkable Disconnect between Antigen Structural Homology and T Cell Recognition.
J Mol Biol. 372: 1123-36, 2007.
91)  Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z, Antony PA, Gattinoni L, Rosenberg SA, Restifo NP.
Toll-like receptors in tumor immunotherapy.
Clin. Cancer Res. 13: 5280-9, 2007.
92)  Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP.
Adoptive immunotherapy for cancer: building on success.
Nat. Rev. Immunol. 6: 383-93, 2006.
93)  Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, Sakaguchi S, Houghton AN.
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.
Cancer Res. 66: 4904-12, 2006.
94)  Rosenberg SA, Sherry RM, Morton KE, Yang JC, Topalian SL, Royal RE, Kammula US, Restifo NP, Hughes MS, Schwarz SL, Ngo LT, Mavroukakis SA, White DE.
Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines.
J. Immunother. 29: 224-31, 2006.
95)  Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA.
Cancer regression in patients after transfer of genetically engineered lymphocytes.
Science. 314: 126-9, 2006.
96)  Antony PA, Restifo NP.
CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.
J. Immunother. 28: 120-8, 2006.
97)  Klebanoff CA, Gattinoni L, Restifo NP.
CD8+ T-cell memory in tumor immunology and immunotherapy.
Immunol. Rev. 211: 214-24, 2006.
98)  Schiavo R, Baatar D, Olkhanud P, Indig FE, Restifo N, Taub D, Biragyn A.
Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses.
Blood. 107: 4597-605, 2006.
99)  Donohue KB, Grant JM, Tewalt EF, Palmer DC, Theoret MR, Restifo NP, Norbury CC.
Cross-priming utilizes antigen not available to the direct presentation pathway.
Immunology. 119: 63-73, 2006.
100)  Gattinoni L, Ranganathan A, Surman DR, Palmer DC, Antony PA, Theoret MR, Heimann DM, Rosenberg SA, Restifo NP.
CTLA-4 dysregulation of self/tumor-reactive CD8+ T cell function is CD4+ T cell-dependent.
Blood. 108: 3818-23, 2006.
101)  Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y, Zeng G, Wunderlich JR, Nguyen DM, Restifo NP, Schrump DS.
De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.
Cancer Res. 66: 1105-13, 2006.
102)  Lindsey KR, Gritz L, Sherry R, Abati A, Fetsch PA, Goldfeder LC, Gonzales MI, Zinnack KA, Rogers-Freezer L, Haworth L, Mavroukakis SA, White DE, Steinberg SM, Restifo NP, Panicali DL, Rosenberg SA, Topalian SL.
Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.
Clin. Cancer Res. 12: 2526-37, 2006.
103)  Zhao Y, Zheng Z, Cohen CJ, Gattinoni L, Palmer DC, Restifo NP, Rosenberg SA, Morgan RA.
High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation.
Mol. Ther. 13: 151-9, 2006.
104)  Overwijk WW, de Visser KE, Tirion FH, de Jong LA, Pols TW, van der Velden YU, van den Boorn JG, Keller AM, Buurman WA, Theoret MR, Blom B, Restifo NP, Kruisbeek AM, Kastelein RA, Haanen JB.
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.
J. Immunol. 176: 5213-22, 2006.
105)  Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, Restifo NP.
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?.
Nat Clin Pract Oncol. 3: 668-81, 2006.
106)  Antony PA, Paulos CM, Ahmadzadeh M, Akpinarli A, Palmer DC, Sato N, Kaiser A, Hinrichs CS, Heinrichs C, Klebanoff CA, Tagaya Y, Restifo NP.
Interleukin-2-dependent mechanisms of tolerance and immunity in vivo.
J. Immunol. 176: 5255-66, 2006.
107)  Hinrichs CS, Gattinoni L, Restifo NP.
Programming CD8+ T cells for effective immunotherapy.
Curr. Opin. Immunol. 18: 363-70, 2006.
108)  Lee CH, Kakinuma T, Wang J, Zhang H, Palmer DC, Restifo NP, Hwang ST.
Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.
Mol. Cancer Ther. 5: 2592-9, 2006.
109)  Hwang LN, Yu Z, Palmer DC, Restifo NP.
The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor.
Cancer Res. 66: 1132-8, 2006.
110)  Leitner WW, Bergmann-Leitner ES, Hwang LN, Restifo NP.
Type I Interferons are essential for the efficacy of replicase-based DNA vaccines.
Vaccine. 24: 5110-8, 2006.
111)  Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP.
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.
J. Clin. Invest. 115: 1616-26, 2005.
112)  Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA.
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
J. Clin. Oncol. 23: 2346-57, 2005.
113)  Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA.
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
J. Clin. Oncol. 23: 6043-53, 2005.
114)  Charo J, Finkelstein SE, Grewal N, Restifo NP, Robbins PF, Rosenberg SA.
Bcl-2 overexpression enhances tumor-specific T-cell survival.
Cancer Res. 65: 2001-8, 2005.
115)  Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, Rosenberg SA, Restifo NP.
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
J. Immunol. 174: 2591-601, 2005.
116)  Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, Waldmann TA, Restifo NP.
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.
Proc. Natl. Acad. Sci. U.S.A. 102: 9571-6, 2005.
117)  Hinrichs CS, Palmer DC, Rosenberg SA, Restifo NP.
Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells.
J. Immunother. 28: 517-24, 2005.
118)  Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S.
Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy.
J. Immunol. 174: 1462-71, 2005.
119)  Borbulevych OY, Baxter TK, Yu Z, Restifo NP, Baker BM.
Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design.
J. Immunol. 174: 4812-20, 2005.
120)  Wang LX, Li R, Yang G, Lim M, O'Hara A, Chu Y, Fox BA, Restifo NP, Urba WJ, Hu HM.
Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing.
Cancer Res. 65: 10569-77, 2005.
121)  Wrzesinski C, Restifo NP.
Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy.
Curr. Opin. Immunol. 17: 195-201, 2005.
122)  Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP.
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.
J. Exp. Med. 202: 907-12, 2005.
123)  Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP.
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.
Trends Immunol. 26: 111-7, 2005.
124)  Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP, Berzofsky JA, Leonard WJ.
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.
J. Exp. Med. 201: 139-48, 2005.
125)  Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, Schwartzentruber D, Berman DM, Schwarz SL, Ngo LT, Mavroukakis SA, White DE, Steinberg SM.
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.
J. Immunol. 175: 6169-76, 2005.
126)  Restifo NP, Rosenberg SA.
Use of standard criteria for assessment of cancer vaccines.
Lancet Oncol. 6: 3-4, 2005.
127)  Leitner WW, Hwang LN, Bergmann-Leitner ES, Finkelstein SE, Frank S, Restifo NP.
Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines.
Vaccine. 22: 1537-44, 2004.
128)  Finkelstein SE, Heimann DM, Klebanoff CA, Antony PA, Gattinoni L, Hinrichs CS, Hwang LN, Palmer DC, Spiess PJ, Surman DR, Wrzesiniski C, Yu Z, Rosenberg SA, Restifo NP.
Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer.
J. Leukoc. Biol. 76: 333-7, 2004.
129)  Rosenberg SA, Yang JC, Restifo NP.
Cancer immunotherapy: moving beyond current vaccines.
Nat. Med. 10: 909-15, 2004.
130)  Lou Y, Wang G, Lizée G, Kim GJ, Finkelstein SE, Feng C, Restifo NP, Hwu P.
Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.
Cancer Res. 64: 6783-90, 2004.
131)  Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, Tagaya Y, Rosenberg SA, Waldmann TA, Restifo NP.
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.
Proc. Natl. Acad. Sci. U.S.A. 101: 1969-74, 2004.
132)  Yu Z, Theoret MR, Touloukian CE, Surman DR, Garman SC, Feigenbaum L, Baxter TK, Baker BM, Restifo NP.
Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance.
J. Clin. Invest. 114: 551-9, 2004.
133)  Palmer DC, Balasubramaniam S, Hanada K, Wrzesinski C, Yu Z, Farid S, Theoret MR, Hwang LN, Klebanoff CA, Gattinoni L, Goldstein AL, Yang JC, Restifo NP.
Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
J. Immunol. 173: 7209-16, 2004.
134)  Leitner WW, Hwang LN, deVeer MJ, Zhou A, Silverman RH, Williams BR, Dubensky TW, Ying H, Restifo NP.
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways.
Nat. Med. 9: 33-9, 2003.
135)  Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA.
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Proc. Natl. Acad. Sci. U.S.A. 100: 8372-7, 2003.
136)  Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, Schwartzentruber DJ, Topalian SL, Restifo NP, Filie A, Chang R, Dudley ME.
Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.
J. Immunother. 26: 385-93, 2003.
137)  Leitner WW, Restifo NP.
DNA vaccines and apoptosis: to kill or not to kill?.
J. Clin. Invest. 112: 22-4, 2003.
138)  Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, Theoret MR, Wunderlich JR, Hughes MS, Restifo NP, Rosenberg SA.
High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
J. Immunol. 171: 3287-95, 2003.
139)  Murakami T, Cardones AR, Finkelstein SE, Restifo NP, Klaunberg BA, Nestle FO, Castillo SS, Dennis PA, Hwang ST.
Immune evasion by murine melanoma mediated through CC chemokine receptor-10.
J. Exp. Med. 198: 1337-47, 2003.
140)  Phan GQ, Touloukian CE, Yang JC, Restifo NP, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE, Rosenberg SA.
Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens.
J. Immunother. 26: 349-56, 2003.
141)  Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE.
Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.
Hum. Gene Ther. 14: 709-14, 2003.
142)  Touloukian CE, Leitner WW, Schnur RE, Robbins PF, Li Y, Southwood S, Sette A, Rosenberg SA, Restifo NP.
Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.
J. Immunol. 170: 1579-85, 2003.
143)  Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, Gritz L, Panicali DL, White DE.
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
Clin. Cancer Res. 9: 2973-80, 2003.
144)  Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP.
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
J. Exp. Med. 198: 569-80, 2003.
145)  Neeley YC, McDonagh KT, Overwijk WW, Restifo NP, Sanda MG.
Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
Prostate. 53: 183-91, 2002.
146)  Restifo NP, Antony PA, Finkelstein SE, Leitner WW, Surman DP, Theoret MR, Touloukian CE.
Assumptions of the tumor 'escape' hypothesis.
Semin. Cancer Biol. 12: 81-6, 2002.
147)  Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA.
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
Science. 298: 850-4, 2002.
148)  Yu Z, Restifo NP.
Cancer vaccines: progress reveals new complexities.
J. Clin. Invest. 110: 289-94, 2002.
149)  Antony PA, Restifo NP.
Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?.
J. Immunother. 25: 202-6, 2002.
150)  Touloukian CE, Leitner WW, Robbins PF, Li YF, Kang X, Lapointe R, Hwu P, Rosenberg SA, Restifo NP.
Expression of a.
Cancer Res. 62: 5144-7, 2002.
151)  Wang HY, Fu T, Wang G, Zeng G, Perry-Lalley DM, Yang JC, Restifo NP, Hwu P, Wang RF.
Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells.
J. Clin. Invest. 109: 1463-70, 2002.
152)  Perez-Diez A, Spiess PJ, Restifo NP, Matzinger P, Marincola FM.
Intensity of the vaccine-elicited immune response determines tumor clearance.
J. Immunol. 168: 338-47, 2002.
153)  Sloan JM, Kershaw MH, Touloukian CE, Lapointe R, Robbins PF, Restifo NP, Hwu P.
MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells.
Cancer Gene Ther. 9: 946-50, 2002.
154)  Khong HT, Restifo NP.
Natural selection of tumor variants in the generation of.
Nat. Immunol. 3: 999-1005, 2002.
155)  Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA.
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.
J. Clin. Oncol. 20: 142-52, 2002.
156)  Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Diez A, Petersen D, Zhao Y, Simon R, Powell JI, Asaki E, Alexander HR, Duray PH, Herlyn M, Restifo NP, Liu ET, Rosenberg SA, Marincola FM.
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness.
Cancer Res. 62: 3581-6, 2002.
157)  Overwijk WW, Restifo NP.
B16 as a mouse model for human melanoma.
Curr Protoc Immunol. Chapter 20: Unit 20.1, 2001.
158)  Restifo NP.
Countering the 'counterattack' hypothesis.
Nat. Med. 7: 259, 2001.
159)  Overwijk WW, Restifo NP.
Creating therapeutic cancer vaccines: notes from the battlefield.
Trends Immunol. 22: 5-7, 2001.
160)  van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP.
Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy.
J. Exp. Med. 194: 481-9, 2001.
161)  Restifo NP.
Hierarchy, tolerance, and dominance in the antitumor T-cell response.
J. Immunother. 24: 193-4, 2001.
162)  Kershaw MH, Hsu C, Mondesire W, Parker LL, Wang G, Overwijk WW, Lapointe R, Yang JC, Wang RF, Restifo NP, Hwu P.
Immunization against endogenous retroviral tumor-associated antigens.
Cancer Res. 61: 7920-4, 2001.
163)  Touloukian CE, Leitner WW, Robbins PF, Rosenberg SA, Restifo NP.
Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen.
Cancer Res. 61: 8100-4, 2001.
164)  Restifo NP.
Vaccines to die for.
Nat. Biotechnol. 19: 527-8, 2001.
165)  Xiang R, Lode HN, Chao TH, Ruehlmann JM, Dolman CS, Rodriguez F, Whitton JL, Overwijk WW, Restifo NP, Reisfeld RA.
An autologous oral DNA vaccine protects against murine melanoma.
Proc. Natl. Acad. Sci. U.S.A. 97: 5492-7, 2000.
166)  Feldman AL, Restifo NP, Alexander HR, Bartlett DL, Hwu P, Seth P, Libutti SK.
Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice.
Cancer Res. 60: 1503-6, 2000.
167)  Charles LG, Xie YC, Restifo NP, Roessler B, Sanda MG.
Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development.
World J Urol. 18: 136-42, 2000.
168)  Overwijk WW, Restifo NP.
Autoimmunity and the immunotherapy of cancer: targeting the.
Crit. Rev. Immunol. 20: 433-50, 2000.
169)  Restifo NP.
Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity.
Curr. Opin. Immunol. 12: 597-603, 2000.
170)  Surman DR, Dudley ME, Overwijk WW, Restifo NP.
Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.
J. Immunol. 164: 562-5, 2000.
171)  Lee K, Overwijk WW, O'Toole M, Swiniarski H, Restifo NP, Dorner AJ, Wolf SF, Sturmhoefel K.
Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses.
J. Interferon Cytokine Res. 20: 589-96, 2000.
172)  Leitner WW, Ying H, Driver DA, Dubensky TW, Restifo NP.
Enhancement of tumor-specific immune response with plasmid DNA replicon vectors.
Cancer Res. 60: 51-5, 2000.
173)  Bronte V, Apolloni E, Ronca R, Zamboni P, Overwijk WW, Surman DR, Restifo NP, Zanovello P.
Genetic vaccination with.
Cancer Res. 60: 253-8, 2000.
174)  Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, Restifo NP, Zanovello P.
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.
Blood. 96: 3838-46, 2000.
175)  Touloukian CE, Leitner WW, Topalian SL, Li YF, Robbins PF, Rosenberg SA, Restifo NP.
Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.
J. Immunol. 164: 3535-42, 2000.
176)  Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF.
Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.
J. Immunol. 165: 1153-9, 2000.
177)  Restifo NP.
Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.
Nat. Med. 6: 493-5, 2000.
178)  Colella TA, Bullock TN, Russell LB, Mullins DW, Overwijk WW, Luckey CJ, Pierce RA, Restifo NP, Engelhard VH.
Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy.
J. Exp. Med. 191: 1221-32, 2000.
179)  Overwijk WW, Theoret MR, Restifo NP.
The future of interleukin-2: enhancing therapeutic anticancer vaccines.
Cancer J Sci Am. 6 Suppl 1: S76-80, 2000.
180)  Restifo NP, Ying H, Hwang L, Leitner WW.
The promise of nucleic acid vaccines.
Gene Ther. 7: 89-92, 2000.
181)  Ying H, Zaks TZ, Wang RF, Irvine KR, Kammula US, Marincola FM, Leitner WW, Restifo NP.
Cancer therapy using a self-replicating RNA vaccine.
Nat. Med. 5: 823-7, 1999.
182)  Restifo NP, Rosenberg SA.
Developing recombinant and synthetic vaccines for the treatment of melanoma.
Curr Opin Oncol. 11: 50-7, 1999.
183)  Leitner WW, Ying H, Restifo NP.
DNA and RNA-based vaccines: principles, progress and prospects.
Vaccine. 18: 765-77, 1999.
184)  Zaks TZ, Chappell DB, Rosenberg SA, Restifo NP.
Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition.
J. Immunol. 162: 3273-9, 1999.
185)  Chappell DB, Zaks TZ, Rosenberg SA, Restifo NP.
Human melanoma cells do not express Fas (Apo-1/CD95) ligand.
Cancer Res. 59: 59-62, 1999.
186)  Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Sznol M, Schwarz SL, Spiess PJ, Wunderlich JR, Seipp CA, Einhorn JH, Rogers-Freezer L, White DE.
Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.
J. Immunol. 163: 1690-5, 1999.
187)  Xie YC, Hwang C, Overwijk W, Zeng Z, Eng MH, Mulé JJ, Imperiale MJ, Restifo NP, Sanda MG.
Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen.
J. Natl. Cancer Inst. 91: 169-75, 1999.
188)  Kaufman HL, Rao JB, Irvine KR, Bronte V, Rosenberg SA, Restifo NP, Irivine KR.
Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model.
J. Immunother. 22: 489-96, 1999.
189)  Cormier JN, Panelli MC, Hackett JA, Bettinotti MP, Mixon A, Wunderlich J, Parker LL, Restifo NP, Ferrone S, Marincola FM.
Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model.
Int. J. Cancer. 80: 781-90, 1999.
190)  Irvine KR, Parkhurst MR, Shulman EP, Tupesis JP, Custer M, Touloukian CE, Robbins PF, Yafal AG, Greenhalgh P, Sutmuller RP, Offringa R, Rosenberg SA, Restifo NP.
Recombinant virus vaccination against.
Cancer Res. 59: 2536-40, 1999.
191)  Terenzi F, deVeer MJ, Ying H, Restifo NP, Williams BR, Silverman RH.
The antiviral enzymes PKR and RNase L suppress gene expression from viral and non-viral based vectors.
Nucleic Acids Res. 27: 4369-75, 1999.
192)  Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, Restifo NP.
Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.
J. Immunol. 162: 5728-37, 1999.
193)  Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP.
Vaccination with a recombinant vaccinia virus encoding a.
Proc. Natl. Acad. Sci. U.S.A. 96: 2982-7, 1999.
194)  Bronte V, Wang M, Overwijk WW, Surman DR, Pericle F, Rosenberg SA, Restifo NP.
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.
J. Immunol. 161: 5313-20, 1998.
195)  Restifo NP.
Cancer vaccines '98: a reductionistic approach. Bethesda, MD, USA, 27-28 April 1998.
Mol Med Today. 4: 327, 1998.
196)  Gurunathan S, Irvine KR, Wu CY, Cohen JI, Thomas E, Prussin C, Restifo NP, Seder RA.
CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge.
J. Immunol. 161: 4563-71, 1998.
197)  Carroll MW, Overwijk WW, Surman DR, Tsung K, Moss B, Restifo NP.
Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen.
J. Natl. Cancer Inst. 90: 1881-7, 1998.
198)  Surman DR, Irvine KR, Shulman EP, Allweis TM, Rosenberg SA, Restifo NP.
Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization.
J. Immunol. Methods. 214: 51-62, 1998.
199)  Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP.
gp100/pmel 17 is a murine tumor rejection antigen: induction of.
J. Exp. Med. 188: 277-86, 1998.
200)  Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Seipp CA, Einhorn JH, Roberts B, White DE.
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.
J. Natl. Cancer Inst. 90: 1894-900, 1998.
201)  Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE.
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.
Nat. Med. 4: 321-7, 1998.
202)  Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN.
Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization.
J. Exp. Med. 188: 1075-82, 1998.
203)  Chappell DB, Restifo NP.
T cell-tumor cell: a fatal interaction?.
Cancer Immunol. Immunother. 47: 65-71, 1998.
204)  Restifo NP, Surman DR, Zheng H, Palese P, Rosenberg SA, García-Sastre A.
Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer.
Virology. 249: 89-97, 1998.
205)  Bronte V, Carroll MW, Goletz TJ, Wang M, Overwijk WW, Marincola F, Rosenberg SA, Moss B, Restifo NP.
Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine.
Proc. Natl. Acad. Sci. U.S.A. 94: 3183-8, 1997.
206)  Zhai Y, Yang JC, Spiess P, Nishimura MI, Overwijk WW, Roberts B, Restifo NP, Rosenberg SA.
Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.
J. Immunother. 20: 15-25, 1997.
207)  Kim CJ, Prevette T, Cormier J, Overwijk W, Roden M, Restifo NP, Rosenberg SA, Marincola FM.
Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.
J. Immunother. 20: 276-86, 1997.
208)  Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM.
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.
Cancer J Sci Am. 3: 37-44, 1997.
209)  Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP.
Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors.
J. Natl. Cancer Inst. 89: 1595-601, 1997.
210)  Carroll MW, Overwijk WW, Chamberlain RS, Rosenberg SA, Moss B, Restifo NP.
Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.
Vaccine. 15: 387-94, 1997.
211)  Overwijk WW, Surman DR, Tsung K, Restifo NP.
Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for.
Methods. 12: 117-23, 1997.
212)  Porgador A, Mandelboim O, Restifo NP, Strominger JL.
Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy.
Proc. Natl. Acad. Sci. U.S.A. 94: 13140-5, 1997.
213)  Irvine KR, Chamberlain RS, Shulman EP, Rosenberg SA, Restifo NP.
Route of immunization and the therapeutic impact of recombinant anticancer vaccines.
J. Natl. Cancer Inst. 89: 390-2, 1997.
214)  Chamberlain RS, Carroll MW, Bronte V, Hwu P, Warren S, Yang JC, Nishimura M, Moss B, Rosenberg SA, Restifo NP.
Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines.
Cancer Res. 56: 2832-6, 1996.
215)  Irvine KR, Rao JB, Rosenberg SA, Restifo NP.
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.
J. Immunol. 156: 238-45, 1996.
216)  Moss B, Carroll MW, Wyatt LS, Bennink JR, Hirsch VM, Goldstein S, Elkins WR, Fuerst TR, Lifson JD, Piatak M, Restifo NP, Overwijk W, Chamberlain R, Rosenberg SA, Sutter G.
Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates.
Adv. Exp. Med. Biol. 397: 7-13, 1996.
217)  Rao JB, Chamberlain RS, Bronte V, Carroll MW, Irvine KR, Moss B, Rosenberg SA, Restifo NP.
IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
J. Immunol. 156: 3357-65, 1996.
218)  Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA.
Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
J. Natl. Cancer Inst. 88: 100-8, 1996.
219)  Restifo NP.
Recombinant anticancer vaccines.
Cancer J Sci Am. 2: 16-8, 1996.
220)  Restifo NP.
The new vaccines: building viruses that elicit antitumor immunity.
Curr. Opin. Immunol. 8: 658-63, 1996.
221)  Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP.
Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.
J. Immunol. 156: 224-31, 1996.
222)  Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA, Restifo NP.
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.
J. Immunol. 154: 4685-92, 1995.
223)  Wang M, Chen PW, Bronte V, Rosenberg SA, Restifo NP.
Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen.
J Immunother Emphasis Tumor Immunol. 18: 139-46, 1995.
224)  Restifo NP, Bacík I, Irvine KR, Yewdell JW, McCabe BJ, Anderson RW, Eisenlohr LC, Rosenberg SA, Bennink JR.
Antigen processing in vivo and the elicitation of primary CTL responses.
J. Immunol. 154: 4414-22, 1995.
225)  Jakobsen MK, Restifo NP, Cohen PA, Marincola FM, Cheshire LB, Linehan WM, Rosenberg SA, Alexander RB.
Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line.
J Immunother Emphasis Tumor Immunol. 17: 222-8, 1995.
226)  Marincola FM, Shamamian P, Rivoltini L, Salgaller M, Cormier J, Restifo NP, Simonis TB, Venzon D, White DE, Parkinson DR.
HLA associations in the antitumor response against malignant melanoma.
J Immunother Emphasis Tumor Immunol. 18: 242-52, 1995.
227)  Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, Restifo NP.
IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.
J. Immunol. 154: 5282-92, 1995.
228)  McCabe BJ, Irvine KR, Nishimura MI, Yang JC, Spiess PJ, Shulman EP, Rosenberg SA, Restifo NP.
Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.
Cancer Res. 55: 1741-7, 1995.
229)  Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, Simons JW.
Molecular characterization of defective antigen processing in human prostate cancer.
J. Natl. Cancer Inst. 87: 280-5, 1995.
230)  Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifo NP, Topalian SL, Simonis TB, Rosenberg SA.
Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.
Cancer Res. 55: 3149-57, 1995.
231)  Irvine KR, McCabe BJ, Rosenberg SA, Restifo NP.
Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL.
J. Immunol. 154: 4651-7, 1995.
232)  Irvine KR, Restifo NP.
The next wave of recombinant and synthetic anticancer vaccines.
Semin. Cancer Biol. 6: 337-47, 1995.
233)  Restifo NP, Minev BR, Taggarse AS, McFarland BJ, Wang M, Irvine KR.
Enhancing the recognition of tumour associated antigens.
Folia Biol. (Praha). 40: 74-88, 1994.
234)  Minev BR, McFarland BJ, Spiess PJ, Rosenberg SA, Restifo NP.
Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice.
Cancer Res. 54: 4155-61, 1994.
235)  Marincola FM, Shamamian P, Simonis TB, Abati A, Hackett J, O'Dea T, Fetsch P, Yannelli J, Restifo NP, Mulé JJ.
Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.
J Immunother Emphasis Tumor Immunol. 16: 13-23, 1994.
236)  Lawson CM, Bennink JR, Restifo NP, Yewdell JW, Murphy BR.
Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge.
J. Virol. 68: 3505-11, 1994.
237)  Shamamian P, Mancini M, Kawakami Y, Restifo NP, Rosenberg SA, Topalian SL.
Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest.
Cancer Immunol. Immunother. 39: 73-83, 1994.
238)  Marincola FM, Ettinghausen S, Cohen PA, Cheshire LB, Restifo NP, Mulé JJ, Rosenberg SA.
Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha.
J. Immunol. 152: 3500-13, 1994.
239)  Karp SE, Farber A, Salo JC, Hwu P, Jaffe G, Asher AL, Shiloni E, Restifo NP, Mulé JJ, Rosenberg SA.
Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor.
J. Immunol. 150: 896-908, 1993.
240)  O'Neil BH, Kawakami Y, Restifo NP, Bennink JR, Yewdell JW, Rosenberg SA.
Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA.
J. Immunol. 151: 1410-8, 1993.
241)  Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mulé JJ, Rosenberg SA, Bennink JR.
Identification of human cancers deficient in antigen processing.
J. Exp. Med. 177: 265-72, 1993.
242)  Restifo NP, Kawakami Y, Marincola F, Shamamian P, Taggarse A, Esquivel F, Rosenberg SA.
Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.
J. Immunother. 14: 182-90, 1993.
243)  Shiloni E, Karp SE, Custer MC, Shilyansky J, Restifo NP, Rosenberg SA, Mulé JJ.
Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor.
Cancer Immunol. Immunother. 37: 286-92, 1993.
244)  Kawakami Y, Nishimura MI, Restifo NP, Topalian SL, O'Neil BH, Shilyansky J, Yannelli JR, Rosenberg SA.
T-cell recognition of human melanoma antigens.
J. Immunother. 14: 88-93, 1993.
245)  Restifo NP, Spiess PJ, Karp SE, Mulé JJ, Rosenberg SA.
A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.
J. Exp. Med. 175: 1423-31, 1992.
246)  Karp SE, Hwu P, Farber A, Restifo NP, Kriegler M, Mulé JJ, Rosenberg SA.
In vivo activity of tumor necrosis factor (TNF) mutants. Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor.
J. Immunol. 149: 2076-81, 1992.
247)  Restifo NP, Esquivel F, Asher AL, Stötter H, Barth RJ, Bennink JR, Mulé JJ, Yewdell JW, Rosenberg SA.
Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response.
J. Immunol. 147: 1453-9, 1991.
248)  Asher AL, Mulé JJ, Kasid A, Restifo NP, Salo JC, Reichert CM, Jaffe G, Fendly B, Kriegler M, Rosenberg SA.
Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors.
J. Immunol. 146: 3227-34, 1991.
249)  Pisters PW, Restifo NP, Cersosimo E, Brennan MF.
The effects of euglycemic hyperinsulinemia and amino acid infusion on regional and whole body glucose disposal in man.
Metab. Clin. Exp. 40: 59-65, 1991.
Click Here to View Collapsed Bibliography.

This page was last updated on 5/25/2013.